HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Richard L. Prager David H. Johnson Harvey W. Bender, Jr. Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Prager, R. L. Articles by Bender, H. W. Search for Related Content PubMed PubMed Citation Articles by Prager, R. L. Articles by Bender, H. W., Jr.

Ann Thorac Surg 1984;38:622-626
© 1984 The Society of Thoracic Surgeons

---

Articles

The Feasibility of Adjuvant Surgery in Limited-Stage Small Cell Carcinoma: A Prospective Evaluation

Department of Cardiac and Thoracic Surgery and the Division of Oncology, Vanderbilt University Medical Center, Nashville, TN

^* Address reprint requests to Dr. Prager, St. Joseph Mercy Hospital, Professional Office Building, PO Box 994, Ann Arbor, MI 48106

Forty patients with limited-stage small cell carcinoma of the lung were prospectively evaluated for adjuvant surgery after intensive chemotherapy to determine resectability. All patients giving informed consent and having a Karnofsky performance status greater than or equal to 50% were included in the study, which ran from May, 1980, to September, 1982. Ages ranged from 40 to 70 years (median, 59 years). One patient was lost to follow-up. Thirty-nine patients were evaluated for operation 9 to 15 weeks after diagnosis and after having received two to four cycles of chemotherapy intravenously every 3 weeks (cyclophosphamide, 1,000 mg/m²; doxorubicin, 50 mg/m²; vincristine, 1 mg/m²; VP-16, 300 mg/m²). Two patients had clinical Stage I tumors; 12 patients, Stage II; and 25 patients, Stage III. At the time of reevaluation there were 13 (33%) complete responders, 21 (54%) partial responders, and 5 (13%) with stable disease. Eleven (28%) of the 39 patients underwent thoracotomy using standard resection criteria for non–small cell carcinoma. Eight of these 11 had resectable lesions (2, Stage I; 3, Stage II; 3, Stage III); five pneumonectomies and three lobectomies were performed. Tumor was present in six of eight specimens. Twenty-eight patients were not candidates for operation for various reasons: poor pulmonary function, 5; unresectable tumors, 10; refusal, 6; very poor medical condition, 6; and primary site not identified, 1. Median survival for complete responders was 17 months and for partial responders, 11 months.

We have prospectively identified suitable candidates for adjuvant surgery among the total group (denominator population) of patients with limited-stage small cell carcinoma. Operation was performed in only 11 of 39 patients and resection, in 8. For 28 patients with this disease, adjuvant surgery was not appropriate. Also, it appears that resection is applicable in only a selected subset of patients with this tumor.

This article has been cited by other articles:

				R. J. Downey and L. M. Krug Surgery in the Management of Small Cell Lung Cancer J Natl Compr Canc Netw, March 1, 2004; 2(2): 159 - 162. [Abstract] [PDF]

				T. Lewinski, M. zulawski, C. Turski, and A. Pietraszek Small cell lung cancer I-III A: cytoreductive chemotherapy followed by resection with continuation of chemotherapy Eur J Cardiothorac Surg, August 1, 2001; 20(2): 391 - 398. [Abstract] [Full Text] [PDF]

				D. W. McFadden, M. Rudnicki, and M. A. Talamini Primary small cell carcinoma of the esophagus Ann. Thorac. Surg., March 1, 1989; 47(3): 477 - 480. [Abstract] [PDF]

				B. L. Graham Jr., L. Balducci, T. Khansur, M. L. Dalton, and B. Lambuth Surgery in Small Cell Lung Cancer Ann. Thorac. Surg., June 1, 1988; 45(6): 687 - 692. [Abstract] [PDF]